Association between toxoplasmosis and autoimmune rheumatic diseases in Egyptian patients
Copyright © 2023. Published by Elsevier España, S.L.U..
PURPOSE: To explore the association between T. gondii and autoimmune rheumatic diseases (ARDs).
METHODS: This study involved 82 patients with ARDs: 44 rheumatoid arthritis (RA), 28 systemic lupus erythematosus (SLE), and 10 systemic sclerosis (SSc) and 61 age- and sex-matched controls. Sociodemographic, clinical, and laboratory data were collected, and disease activity was assessed. Exposure to toxoplasmosis risk factors was investigated. Serological tests for anti-Toxoplasma IgM and IgG antibodies were assessed using ELISA.
RESULTS: In SLE patients, a significant difference of T. gondii IgM versus controls was detected (P=.03). In RA and SLE patients, T. gondii IgG showed a significant difference versus controls (34 (77.3%) P=.001 and 18 (64.3%) P=.03, respectively). There was no significant difference in SSc versus controls. Fetal congenital anomalies displayed a significant difference in IgM seropositive compared to seronegative patients (P=.04). Cat exposure showed a significant difference between IgM and IgG seropositive versus seronegative patients (12 (80.0%) P=.02 and 34 (59.6) P=.04, respectively). There was no significant difference in seropositive patients regarding history of abortion, neuro-psychiatric manifestations, disease activity parameters (ESR, CRP), or different regimens of medications.
CONCLUSION: Toxoplasma IgM seropositivity is associated with SLE patients. T. gondii IgG seropositivity is associated with both RA and SLE patients. However, Toxoplasma seropositivity had no association with SSc patients. An association between fetal congenital anomalies and IgM seropositivity was demonstrated. A linkage between cat exposure as a risk factor and toxoplasmosis was suggested among ARD patiants. Exploration of impact of toxoplasmosis on ARDs is a necessity through randomized controlled trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Reumatologia clinica - 19(2023), 9 vom: 09. Nov., Seite 488-494 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aboukamar, Wafaa A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.11.2023 Date Revised 13.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.reumae.2023.03.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364368934 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364368934 | ||
| 003 | DE-627 | ||
| 005 | 20231226095304.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.reumae.2023.03.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1214.xml |
| 035 | |a (DE-627)NLM364368934 | ||
| 035 | |a (NLM)37945182 | ||
| 035 | |a (PII)S2173-5743(23)00104-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aboukamar, Wafaa A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association between toxoplasmosis and autoimmune rheumatic diseases in Egyptian patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.11.2023 | ||
| 500 | |a Date Revised 13.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier España, S.L.U. | ||
| 520 | |a PURPOSE: To explore the association between T. gondii and autoimmune rheumatic diseases (ARDs) | ||
| 520 | |a METHODS: This study involved 82 patients with ARDs: 44 rheumatoid arthritis (RA), 28 systemic lupus erythematosus (SLE), and 10 systemic sclerosis (SSc) and 61 age- and sex-matched controls. Sociodemographic, clinical, and laboratory data were collected, and disease activity was assessed. Exposure to toxoplasmosis risk factors was investigated. Serological tests for anti-Toxoplasma IgM and IgG antibodies were assessed using ELISA | ||
| 520 | |a RESULTS: In SLE patients, a significant difference of T. gondii IgM versus controls was detected (P=.03). In RA and SLE patients, T. gondii IgG showed a significant difference versus controls (34 (77.3%) P=.001 and 18 (64.3%) P=.03, respectively). There was no significant difference in SSc versus controls. Fetal congenital anomalies displayed a significant difference in IgM seropositive compared to seronegative patients (P=.04). Cat exposure showed a significant difference between IgM and IgG seropositive versus seronegative patients (12 (80.0%) P=.02 and 34 (59.6) P=.04, respectively). There was no significant difference in seropositive patients regarding history of abortion, neuro-psychiatric manifestations, disease activity parameters (ESR, CRP), or different regimens of medications | ||
| 520 | |a CONCLUSION: Toxoplasma IgM seropositivity is associated with SLE patients. T. gondii IgG seropositivity is associated with both RA and SLE patients. However, Toxoplasma seropositivity had no association with SSc patients. An association between fetal congenital anomalies and IgM seropositivity was demonstrated. A linkage between cat exposure as a risk factor and toxoplasmosis was suggested among ARD patiants. Exploration of impact of toxoplasmosis on ARDs is a necessity through randomized controlled trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anticuerpo IgG | |
| 650 | 4 | |a Anticuerpo IgM | |
| 650 | 4 | |a Autoimmune rheumatic diseases | |
| 650 | 4 | |a ELISA | |
| 650 | 4 | |a Enfermedades reumáticas autoinmunes | |
| 650 | 4 | |a IgG antibody | |
| 650 | 4 | |a IgM antibody | |
| 650 | 4 | |a Seroprevalence | |
| 650 | 4 | |a Seroprevalencia | |
| 650 | 4 | |a Toxoplasma gondii | |
| 650 | 7 | |a Antibodies, Protozoan |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 700 | 1 | |a Habib, Samar |e verfasserin |4 aut | |
| 700 | 1 | |a Tharwat, Samar |e verfasserin |4 aut | |
| 700 | 1 | |a Nassar, Mohamed Kamal |e verfasserin |4 aut | |
| 700 | 1 | |a Elzoheiry, Manal A |e verfasserin |4 aut | |
| 700 | 1 | |a Atef, Rania |e verfasserin |4 aut | |
| 700 | 1 | |a Elmehankar, Manar S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Reumatologia clinica |d 2011 |g 19(2023), 9 vom: 09. Nov., Seite 488-494 |w (DE-627)NLM213092891 |x 2173-5743 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:9 |g day:09 |g month:11 |g pages:488-494 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.reumae.2023.03.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 9 |b 09 |c 11 |h 488-494 | ||